Skip to main content

Table 4 Cell cycle alteration after bortezomib treatment

From: Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

Cell line Group Percentage of cells in different cell cycle phases (%)
Phase G1 Phase S Phase G2
U251 Control 43.87 ± 2.77 38.12 ± 3.50 18.01 ± 2.23
10 nmol/L 54.44 ± 6.32 33.42 ± 3.22 12.15 ± 1.22
20 nmol/L 70.83 ± 7.54 22.42 ± 2.52 6.74 ± 2.10
U87 Control 45.97 ± 2.99 37.06 ± 2.52 16.97 ± 1.88
10 nmol/L 53.1 ± 64.3 32.41 ± 2.21 14.43 ± 1.90
20 nmol/L 76.35 ± 6.54 14.89 ± 1.50 8.76 ± 2.22